Attached files
file | filename |
---|---|
8-K - REPROS THERAPEUTICS INC. | v210473_8k.htm |
EX-4.1 - REPROS THERAPEUTICS INC. | v210473_ex4-1.htm |
EX-1.1 - REPROS THERAPEUTICS INC. | v210473_ex1-1.htm |
EX-4.2 - REPROS THERAPEUTICS INC. | v210473_ex4-2.htm |
Exhibit
99.1
Contact:
|
Repros
Therapeutics Inc.
Joseph
Podolski (281) 719-3447
President
and Chief Executive
Officer
|
REPROS
THERAPEUTICS® ANNOUNCES PRICING OF
PUBLIC
OFFERING OF COMMON STOCK AND WARRANTS
THE
WOODLANDS, Texas – February 3, 2011 – Repros Therapeutics Inc.® (NasdaqCM:RPRX)
today announced the pricing of its public offering of 690,000 units, (including
the exercise of the underwriter’s overallotment option), consisting of 2,760,000
shares of its common stock, Series A Warrants to purchase 2,070,000 shares of
common stock and Series B warrants to purchase 1,690,500 shares of its common
stock, at a price per unit of $17.15. Each unit consists of four shares of
common stock, Series A Warrants exercisable for three shares of common stock at
an exercise price of $0.01 per share and Series B Warrants exercisable for 2.45
shares of common stock at an exercise price of $2.49 per share. Gross proceeds
to Repros, after the underwriting discount and before offering expenses, are
expected to be approximately $11,000,000. Upon the closing of this offering, the
Series A Warrants and Series B Warrants will be listed on the Nasdaq Capital
Market under the symbols “RPRXW” and “RPRXZ,” respectively. The offering is
expected to close on or about February 8, 2011.
Ladenburg
Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services
Inc. (NYSE Amex: LTS), is acting as the sole underwriter in connection with the
offering.
“This
offering is expected to provide Repros funding into mid-2012,” Joseph S.
Podolski, CEO, said. “It should allow us to complete both of our Androxal®
clinical trials currently underway, as well as our low dose Proellex® study.
Assuming successful completion of these studies, Repros anticipates having two
product candidates ready to enter Phase 3 trials during 2012.”
A
registration statement relating to the shares and warrants has been declared
effective by the Securities and Exchange Commission. This communication shall
not constitute an offer to sell or a solicitation of an offer to buy, nor shall
there be any sale of, these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. The shares of common stock
and warrants comprising the units are being offered only pursuant to a
prospectus. A copy of the prospectus may be obtained from Ladenburg Thalmann
& Co. Inc., 520 Madison Avenue, 9th floor, New York, NY 10022.
About
Repros Therapeutics Inc.
Repros
Therapeutics focuses on the development of oral small molecule drugs for major
unmet medical needs that treat male and female reproductive
disorders.
Any
statements that are not historical facts contained in this release are
forward-looking statements that involve risks and uncertainties, including the
timing of enrollment of patients into Repros’ current clinical trials and
studies, the outcome of such clinical trial programs, and such other risks which
are identified in the Company's Registration Statement on Form S-1 relating to
the above offering. These documents are available on request from Repros
Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
For more
information, please visit the Company's website at
http://www.reprosrx.com.